🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

RT MIT Alumni: Alum cofounded-Finch Therapeutics is developing treatments for conditions like chronic hepatitis B, Crohn’s disease, and ulcerative colitis…all by harnessing the power of the #microbiome. bit.ly/2XMv3nK

We want to thank Christian and Nora from the Peggy Lillis Foundation for joining us today to share their experiences battling #cdiff. Hearing these types of stories is what fuels our commitment to serving patients. To learn more about the PLF: peggyfoundation.org

Finch is committed to creating a more equitable, diverse and inclusive life sciences industry. As a proud signer of MassBio’s CEO Pledge, we commit to implementing comprehensive ED&I initiatives as we do our part to eliminate racial inequality. bit.ly/3j23xeO

Today Finch announced a $90M Series D financing, fueling the advancement of our pipeline and bringing us one step closer to delivering on our commitment to patients affected by conditions linked to #microbiome disruption. finchtherapeutics.com/blog/finch-the…

We look forward to the upcoming Microbiome Movement Drug Development Summit! On Mon 10/19 at 8:30am ET, our CEO Mark Smith will join the Microbiome Leaders Panel and at 12pm ET, our VP of Research Sonia Timberlake will give a presentation on our platform. microbiome-summit.com

We are proud to have recently presented results from our positive PRISM3 trial of CP101 in recurrent #cdiff at #uegweek and #ACG2020. We are very grateful to the patients that participated in the trial and all the PRISM3 investigators and study staff. finchtherapeutics.com/blog/finch-the…

November is #cdiffawarenessmonth. To effectively fight C. diff, it’s important that infections are tracked. You can help by signing Peggy Lillis Foundation’s petition to make #cdiff a Nationally Notifiable Disease. tinyurl.com/cdiffpetition

November is #cdiffawarenessmonth. We honor the patients and advocates educating and inspiring others and the healthcare professionals and scientists working to find new ways to combat #cdiff. We're honored to work alongside this community to advance patient care.

On Monday November 23, the C DIFF FOUNDATION will host a virtual Patient & Family C. diff Community Symposium. Attendees will learn more about the prevention and treatment of #cdiff and the support available to patients and their families. For more info: cdifffoundation.org/patientfamilys…

Our IPO is an exciting step that will help fuel our mission to transform lives with #microbiome therapeutics. We thank our incredible team members, board members, investors, business partners, and the clinicians and patients that have participated in our clinical trials.

We are looking forward to joining the Peggy Lillis Foundation's Virtual C. diff Advocacy Summit. On Thursday, April 22 at 3pm EST, our Chief Medical Officer, Zain Kassam, MD will be speaking on a panel about #cdiff and the unmet treatment needs. hopin.com/events/2021-na…

We are looking forward to the Microbiome Movement Drug Development Summit. Join us on Wednesday 6/30 to hear our CEO, Mark Smith, and our Senior VP of Research, Sonia Timberlake, discuss our work harnessing the #microbiome. To register visit: microbiome-summit.com.

We are excited to share data from our Phase 2 trial of CP101 for the prevention of recurrent #Cdiff at #ACG2021, including new 24-week efficacy and safety data. Stop by our booth (#1123) to learn more or click here: ir.finchtherapeutics.com/news-releases/…

Today at #ACG2021, we are excited for Jessica R Allegretti to present data from our PRISM3 Phase 2 trial of the investigational #microbiome therapeutic CP101 for the prevention of recurrent #Cdiff. We welcome ACG attendees to stop by our booth to learn more about our work (#1123).

November is #cdiffawarenessmonth. We send our heartfelt gratitude to the many patients, healthcare providers, scientists, patient advocacy groups, and policy makers working together to fight #cdiff. To learn more about C. diff: cdc.gov/cdiff/index.ht… Peggy Lillis Foundation C DIFF FOUNDATION

Recently, our CEO Mark Smith had the pleasure of joining Patrick OShaughnessy on the Business Breakdowns podcast. In the podcast, Mark and Patrick discuss the #microbiome and Finch’s unique approach to drug development. joincolossus.com/episodes/80480… Colossus

We look forward to presenting at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13th at 9:45 am ET. Tune in to learn more about our platform and pipeline of investigational #microbiome therapeutics. ir.finchtherapeutics.com/events/event-d…

If you’re attending #BIO22, we invite you to join our SVP of Research, Sonia Timberlake, for a panel discussion focused on the recent developments in the #microbiome field and the next steps for this exciting new area of drug development. For more details: bio.org/events/bio-int…

Today we announced that Jessica R Allegretti will be presenting CP101 PRISM-EXT data at #ACG2022 and that we have proceeded with patient dosing in PRISM4, our Ph 3 trial of CP101 in recurrent #cdiff. ir.finchtherapeutics.com/news-releases/…

We were honored to recently attend the Peggy Lillis Foundation's Fight #Cdiff Gala. Congrats to Dr Paul Gastro for receiving the Leadership Award and Kee Kee Buckley for receiving the Advocate Award this year! We are grateful for all the incredible work that @ChristianLillis and the PLF do.